病理治疗效果和HPV阴性HNSCC患者的存活率在新辅助药尼沃卢马布之后
Annie E Moroco1, Kathryn Nunes1, Angela Alnemri1
1Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania.
JAMA otolaryngology-- head & neck surgery
|July 31, 2025
概括
在头支状细胞癌 (HNSCC) 中,对新辅助药尼沃卢马布的病理治疗效应 (pTE) 反应可能预测存活率. 呈PTE反应的HPV阴性患者在无病和整体存活期显著改善.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 头部和部癌症研究研究
背景情况:
- 新辅助免疫疗法,特别是尼沃卢马布,对头部和部状细胞癌 (HNSCC) 显示出希望.
- 病理治疗效应 (pTE) 是治疗反应的潜在衡量标准,但其与生存结果的相关性需要进一步调查.
研究的目的:
- 为了确定HNSCC中新辅助药尼沃卢马布的病理反应是否与改善的生存结果相关.
- 评估pTE作为HNSCC治疗疗效的替代标记物的实用性.
主要方法:
- 两项多机构新辅助药临床试验 (NCT03238365,NCT03854032) 的综合分析,涉及可切除HNSCC的患者.
- 患者接受了新辅助药尼沃卢马布,或没有额外的免疫调节药物.
- 使用Kaplan-Meier生存分析来比较pTE响应者和非响应者之间的结果,通过递归分区分析确定了pTE值.
主要成果:
- 确定了57%的pTE值,以区分响应者和非响应者.
- 在HPV阴性HNSCC患者中,病理反应者 (pTE>57%) 显著改善了3年无病生存率 (100%vs66.8%) 和整体生存率 (100%vs73.3%).
- 在HPV阳性HNSCC患者中,响应者和不响应者均表现出高的3年无病生存率 (分别为90%和92.4%).
结论:
- 对新辅助尼沃卢马布的病理反应 (pTE>57%) 可能表明HPV阴性HNSCC患者的生存结果有所改善.
- 在这种情况下,病理治疗效应显示出作为治疗反应的替代标记物的潜力.
- 新辅助免疫疗法策略与HNSCC的生存率改善有关.
相关概念视频
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy
658
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
658
Cancer Survival Analysis
445
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
445
Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509


